透析患者静脉铁剂安全性的系统评价与荟萃分析
该系统评价与荟萃分析纳入7项随机对照试验和15项观察性研究,比较透析患者高剂量与低剂量静脉铁剂、口服铁剂或无铁剂的安全性。随机对照试验显示高剂量静脉铁剂(多数>400 mg/月)与死亡率(RR 0.93,95%CI 0.47-1.84)或感染(RR 1.02,95%CI 0.74-1.41)无显著关联。观察性研究显示高剂量静脉铁剂(多数>200 mg/月)与死亡率、感染、心血管事件或住院无显著关联。
要点
- 高剂量静脉铁剂与透析患者死亡率、感染、心血管事件或住院风险无显著关联。
- 随机对照试验样本量小、事件数少,观察性研究存在统计异质性,证据强度有限。
- 临床决策仍需个体化评估铁剂剂量与潜在风险。
核心结论
- 在透析成人患者中,高剂量静脉铁剂似乎不增加死亡、感染、心血管事件或住院风险。
研究设计与样本
- 系统评价与荟萃分析,检索Medline、EMBASE、Cochrane图书馆和CINAHL至2017年1月6日。
- 纳入比较透析患者高剂量静脉铁剂与低剂量静脉铁剂、口服铁剂或无铁的随机对照试验和观察性研究。
- 共纳入7项随机对照试验和15项观察性研究。
主要发现
- 随机对照试验:高剂量静脉铁剂(多数研究>400 mg/月)与死亡率无关联(6项研究;n=970;合并RR 0.93;95%CI 0.47-1.84;随访35天至26个月)。
- 随机对照试验:高剂量静脉铁剂与感染无关联(4项研究;n=743;RR 1.02;95%CI 0.74-1.41)。
- 观察性研究:高剂量静脉铁剂(多数研究>200 mg/月)与死亡率无关联(8项研究;n=241,408;HR 1.09;95%CI 0.98-1.21;随访3至24个月)。
- 观察性研究:高剂量静脉铁剂与感染无关联(8项研究;n=135,532;合并HR 1.13;95%CI 0.99-1.28)。
- 观察性研究:高剂量静脉铁剂与心血管事件无关联(7项研究;n=135,675;HR 1.18;95%CI 0.90-1.56)。
临床怎么用
- 对于透析患者,高剂量静脉铁剂未显示增加死亡、感染、心血管事件或住院风险,可考虑使用但需个体化评估。
局限性
- 随机对照试验样本量小、事件数少,证据强度有限。
- 观察性研究存在统计异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The safety of intravenous iron dosing in dialysis is uncertain. Higher-dose intravenous iron may be associated with a higher risk of infections, cardiovascular events, hospitalizations, and mortality. This systematic review aimed to determine the safety of higher-dose versus lower-dose intravenous iron, oral iron, or no iron supplementation in adult patients treated with dialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We searched Medline, EMBASE, Cochrane library, and CINAHL from inception to January 6, 2017 for randomized, controlled trials and observational studies comparing higher-dose intravenous iron with lower-dose intravenous iron, oral iron, or no iron in patients treated with dialysis that had all-cause mortality, infection, cardiovascular events, or hospitalizations as outcomes. RESULTS: Of the 2231 eligible studies, seven randomized, controlled trials and 15 observational studies met inclusion criteria. The randomized, controlled trials showed no association between higher-dose intravenous iron (>400 mg/mo for most studies) and mortality (six studies; n=970; pooled relative risk, 0.93; 95% confidence interval, 0.47 to 1.84; follow-up ranging from 35 days to 26 months) or infection (four studies; n=743; relative risk, 1.02; 95% confidence interval, 0.74 to 1.41). The observational studies showed no association between higher-dose intravenous iron (>200 mg/mo for most studies) and mortality (eight studies; n=241,408; hazard ratio, 1.09; 95% confidence interval, 0.98 to 1.21; follow-up ranging from 3 to 24 months), infection (eight studies; n=135,532; pooled hazard ratio, 1.13; 95% confidence interval, 0.99 to 1.28), cardiovascular events (seven studies; n=135,675; hazard ratio, 1.18; 95% confidence interval, 0.90 to 1.56), or hospitalizations (five studies; n=134,324; hazard ratio, 1.08; 95% confidence interval, 0.97 to 1.19). CONCLUSIONS: Higher-dose intravenous iron does not seem to be associated with higher risk of mortality, infection, cardiovascular events, or hospitalizations in adult patients on dialysis. Strength of this finding is limited by small numbers of participants and events in the randomized, controlled trials and statistical heterogeneity in observational studies.
引用
- Hougen I, Collister D, Bourrier M, et al. Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2018. PMID: 29463597. doi:10.2215/CJN.05390517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。